Company intelligence / Profile preview

Neurent Medical

Galway, Galway, Irelandneurentmedical.com ↗

Ownership: Private
Development stage: Commercial

Overview

The NEUROMARK system has received FDA 510(k) clearance for treating chronic rhinitis by targeting and disrupting overactive posterior nasal nerves using impedance-controlled radiofrequency energy. Clinical validation demonstrated significant improvement in symptoms, high safety, and excellent patient tolerability. The company recently completed a successful commercial validation phase with leading ENT specialists.

Therapeutic areas: PulmonologyImmunology
Modalities: DeviceNon-pharmacological therapyRadiofrequency ablation device
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

NEUROMARK

Commercial

Indications: Chronic rhinitis

Partnerships

None specifically disclosed; collaborations with academic institutions and ENT/rhinology specialists are noted.

Beyond the preview

Go deeper on Neurent Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neurent Medical.

Explore the full profile